一分钟看懂
这是一项关于Pheochromocytoma的I 期研究，登记的药物或干预包括([18F]-DOPA)；([18F]-6F-DA)，当前状态为招募中。登记地点显示中国Bethesda有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
([18F]-DOPA)；([18F]-6F-DA) · I 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- National Institutes of Health Clinical Center · Bethesda
公开的入选条件
- Patients are eligible for inclusion in this study if they are adults or children of age 3 years old and up with known, sporadic or familial PHEO/PGL, on the basis of one or more of the following:
- 1. High levels of blood or urinary catecholamines, metanephrines, methoxytyramine or chromogranin A.
- 2. Highly suspected presence of PHEO/PGL based on imaging studies, even with normal biochemistry.
- 3. Personal or family history of PHEO/PGL or genetic pathogenic variants known to predispose individuals to develop PHEO/PGL.
- Signed informed consent is required. The informed consent may be signed by the patient, parent/guardian in pediatric patients or legally authorized representative (LAR) in adults who lack-decision making capacity to consent to research participation.
- Patients must have an outside general practitioner or endocrinologist. Patients with metastatic disease must also have an outside oncologist.
- Family Members of Patients Arm (Linkage Analysis)
- Participants are eligible for inclusion in this study arm if they are:
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT00004847；登记信息更新于 2026-09-16。